Acute myeloid leukemia echocardiograph and ultrasound
Acute myeloid leukemia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Acute myeloid leukemia echocardiograph and ultrasound On the Web |
American Roentgen Ray Society Images of Acute myeloid leukemia echocardiograph and ultrasound |
FDA on Acute myeloid leukemia echocardiograph and ultrasound |
CDC on Acute myeloid leukemia echocardiograph and ultrasound |
Acute myeloid leukemia echocardiograph and ultrasound in the news |
Blogs on Acute myeloid leukemia echocardiograph and ultrasound |
Risk calculators and risk factors for Acute myeloid leukemia echocardiograph and ultrasound |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Overview
Additional imaging studies that can be useful in acute promyelocytic leukemia include echocardiogram, chest X-ray, and brain MRI.
Echocardiograph and ultrasound
- Echocardiogram: An echocardiogram is an essential imaging modality in patients with acute myeloid leukemia receiving anthracycline chemotherapy.[1] Patients who will be receiving anthracycline-based therapy require a baseline echocardiogram to assess the ejection fraction prior to therapy. Anthracyclines are known to cause cardiac toxicity (specifically cardiomyopathy with cumulative anthracycline doses above 500mg/m2). An echocardiogram should be obtained every three months while on therapy with anthracycline. Echocardiogram also applies particularly to cases of high-risk acute promyelocytic leukemia, in which case the standard of care is to give anthracycline along with all-trans retinoic acid.
- ↑ Neilan TG, Coelho-Filho OR, Pena-Herrera D, Shah RV, Jerosch-Herold M, Francis SA; et al. (2012). "Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines". Am J Cardiol. 110 (11): 1679–86. doi:10.1016/j.amjcard.2012.07.040. PMC 3496816. PMID 22917553.